Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Gorman

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Speech, Language, and Hearing Research : JSLHR|July 27, 2019
Clinical Outcomes Following Language-Specific Attention Treatment Versus Direct Attention Training for Aphasia: A Comparative Effectiveness StudyRichard K Peach, Katherine M Beck, Michelle Gorman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2025
Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's DiseaseNicholas Clarke, Peter Thornton, Valérie Reader, et al.
British Journal of Pharmacology|December 3, 2014
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacologyAndrea Cippitelli, Jinhua Wu, Kelly A Gaiolini, et al.
Journal of the American College of Cardiology|May 26, 2026
Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular riskKausik K Ray, Nicholas Clarke, Peter Thornton, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Speech, Language, and Hearing Research : JSLHR|July 27, 2019
Clinical Outcomes Following Language-Specific Attention Treatment Versus Direct Attention Training for Aphasia: A Comparative Effectiveness StudyRichard K Peach, Katherine M Beck, Michelle Gorman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 12, 2025
Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's DiseaseNicholas Clarke, Peter Thornton, Valérie Reader, et al.
British Journal of Pharmacology|December 3, 2014
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacologyAndrea Cippitelli, Jinhua Wu, Kelly A Gaiolini, et al.
Journal of the American College of Cardiology|May 26, 2026
Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular riskKausik K Ray, Nicholas Clarke, Peter Thornton, et al.
Pageof 1